Rheumatologie

Portrait Dr. med. Lukas Wildi

Dr. med. Lukas Wildi

Chefarzt
Rheumatologie

Facharzt für Rheumatologie
Facharzt für Innere Medizin

Aus- und Weiterbildung

2005
Promotion zum Dr. med. der Universität Zürich
Pseudozystische Degeneration des lumbalen Ligamentum flavum

1995 bis 2001
Medizinstudium
Universität Zürich


Berufliche Tätigkeit

seit 11/2017
Chefarzt
Klinik für Rheumatologie
Kantonsspital Winterthur

10/2011 bis 11/2017
Oberarzt
Klinik für Rheumatologie
Universitätsspital Zürich

08/2009 bis 08/2011
Fellowship in Osteoarthritis
Université de Montréal, Kanada

05/2008 bis 06/2009
Assistenzarzt
Innere Medizin A
Kantonsspital Schaffhausen

01/2006 bis 01/2008
Assistenzarzt
Klinik für Rheumatologie
Rheumatologie A
Universitätsspital Zürich

01/2005 bis 12/2005
Assistenzarzt
Rheumatologie
Reha Rheinfelden

01/2003 bis 12/2004
Assistenzarzt
Innere Medizin B
FMI Spital Interlaken

01/2002 bis 12/2002
Assistenzarzt
Allgemeine Chirurgie und Orthopädie
FMI Spital Interlaken


Mitgliedschaften

  • AerzteGesellschaft des Kantons Zürich AGZ
  • Foederatio medicorum helveticorum FMH
  • Rheumaliga Schweiz, Vorstandsmitglied
  • Schweizerische Ärztegesellschaft für Manuelle Medizin
  • Schweizerische Gesellschaft für Ultraschall in der Medizin SGUM
  • Schweizerischer Verband für Assistenz- und Oberärzte VSAO
  • Schweizerische Gesellschaft für Rheumatologie SGR, Vorstandsmitglied seit 08/2016, Delegationsleiter der Weiterbildungsstättenkommission
  • Zürcher Fachärztegesellschaft für Rheumatologie

Originalarbeiten

  1. Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort.
    Hebeisen M, Neuenschwander R, Scherer A, Exer P, Weber U, Tamborrini G, Micheroli R, Wildi LM, Zufferey P, Nissen MJ, Villiger PM, Bernhard J, Finckh A, van der Horst-Bruinsma IE, Sieper J, Landewé R, van der Heijde D, Ciurea A; rheumatologists of the Swiss Clinical Quality Management Program.
    J Rheumatol. 2018 Apr;45(4):506-512. doi: 10.3899/jrheum.170166.
  2. Nodular Regenerative Hyperplasia of the Liver: A Rare Vascular Complication in Systemic Sclerosis.
    Graf L, Dobrota R, Jordan S, Wildi LM, Distler O, Maurer B.
    J Rheumatol. 2018 Jan;45(1):103-106. doi: 10.3899/jrheum.170292.
  3. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort.
    Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, Kissling RO, Tamborrini G, Wildi LM, Nissen MJ, Zufferey P, Bernhard J, Weber U, Landewé RBM, van der Heijde D, Ciurea A; Rheumatologists of the Swiss Clinical Quality Management Program.
    Ann Rheum Dis. 2017 Sep 22. pii: annrheumdis-2017-211544. doi: 10.1136/annrheumdis-2017-211544.
    PMID: 28939631
  4. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.
    Micheroli R, Hebeisen M, Wildi LM, Exer P, Tamborrini G, Bernhard J, Möller B, Zufferey P, Nissen MJ, Scherer A, Ciurea A; Rheumatologists of the Swiss Clinical Quality Management Program.
    Arthritis Res Ther. 2017 Jul 19;19(1):164. doi: 10.1186/s13075-017-1372-3.
    PMID: 28724442
  5. MRI findings in the knee before and after running, with the focus on long distance running: Documentation of irreversible structural damage? A systematic review.
    Hoessly LM, Wildi LM. Am J Sports Med. 2017 Apr;45(5):1206-1217.
  6. Computer-based diagnostic expert systems in rheumatology: where do we stand in 2014?
    Alder H, Michel BA, Marx C, Tamborrini G, Langenegger T, Bruehlmann P, Steurer J, Wildi LM.
    Int J Rheumatol. 2014;2014:672714
  7. Relevant baseline characteristics for describing patients with knee osteoarthritis: results from a Delphi survey.
    Wildi LM, Hensel A, Wertli M, Michel BA, Steurer J.
    BMC Musculoskelet Disord. 2013 Dec 30;14:369
  8. Assessment of cartilage changes over time in knee osteoarthritis disease-modifying osteoarthritis drug trials using semiquantitative and quantitative methods: pros and cons.
    Wildi LM, Martel-Pelletier J, Abram F, Moser T, Raynauld JP, Pelletier JP.
    Arthritis Care Res (Hoboken). 2013 May;65(5):686-94
  9. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI.
    Wildi LM, Raynauld JP, Martel-Pelletier J, Beaulieu A, Bessette L, Morin F, Abram F, Dorais M, Pelletier JP.
    Ann Rheum Dis. 2011 Jun;70(6):982-9
  10. Relationship between bone marrow lesions, cartilage loss and pain in knee osteoarthritis: results from a randomised controlled clinical trial using MRI.
    Wildi LM, Raynauld JP, Martel-Pelletier J, Abram F, Dorais M, Pelletier JP.
    Ann Rheum Dis. 2010 Dec;69(12):2118-24
  11. Pseudocystic degeneration of the lumbar ligamentum flavum: a little known entity.
    Wildi LM, Kurrer MO, Benini A, Weishaupt D, Michel BA, Brühlmann P..
    J Spinal Disord Tech. 2004 Oct;17(5):395-400
  12. Cross-cultural adaptation of the German version of the spinal stenosis measure.
    Wertli MM, Steurer J, Wildi LM, Held U.
    Eur Spine J. 2014 Jun;23(6):1309-19
  13. Reliability and sensitivity to change of IW-TSE versus DESS magnetic resonance imaging sequences in the assessment of bone marrow lesions in knee osteoarthritis patients: Longitudinal data from the Osteoarthritis Initiative (OAI) cohort.
    Raynauld JP, Wildi LM, Abram F, Moser T, Pelletier JP, Martel-Pelletier J. J. Biomedical Science and Engineering, 2013. 6: p. 337-45
  14. Total Knee Replacement as a Knee Osteoarthritis Outcome: Predictors Derived from a 4-Year Long-Term Observation following a Randomized Clinical Trial Using Chondroitin Sulfate.
    Raynauld JP, Martel-Pelletier J, Dorais M, Haraoui B, Choquette D, Abram F, Beaulieu A, Bessette L, Morin F, Wildi LM, Pelletier JP.
    Cartilage. 2013 Jul;4(3):219-26
  15. Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation.
    Raynauld JP, Martel-Pelletier J, Haraoui B, Choquette D, Dorais M, Wildi LM, Abram F, Pelletier JP.
    Ann Rheum Dis. 2011 Aug;70(8):1382-8

Narrative Reviews

  1. Osteoarthritis : What internists should know.
    Wildi L
    Internist (Berl). 2015 May;56(5):527-43
  2. Pharmacological therapy of arthrosis.
    Wildi LM
    Z Rheumatol. 2013 Nov;72(9):885-94
  3. Future therapeutics for osteoarthritis.
    Martel-Pelletier J, Wildi LM, Pelletier JP.
    Bone. 2012 Aug;51(2):297-311

Case Reports

  1. Reversible male infertility under treatment with an anti-TNFα agent: a case report.
    Wildi LM, Haraoui B.
    Ann Rheum Dis. 2012 Mar;71(3):473-4

Buchkapitel

  1. “Biomarkers in Osteoarthritis” in “Understanding Osteoarthritis from Bench to Bedside”
    Wildi LM, Tamborrini G
    Editors Martel-Pelletier J. and Pelletier J.P. Research Signpost, Kerala, India
  • Curriculum vitae

    Aus- und Weiterbildung

    2005
    Promotion zum Dr. med. der Universität Zürich
    Pseudozystische Degeneration des lumbalen Ligamentum flavum

    1995 bis 2001
    Medizinstudium
    Universität Zürich


    Berufliche Tätigkeit

    seit 11/2017
    Chefarzt
    Klinik für Rheumatologie
    Kantonsspital Winterthur

    10/2011 bis 11/2017
    Oberarzt
    Klinik für Rheumatologie
    Universitätsspital Zürich

    08/2009 bis 08/2011
    Fellowship in Osteoarthritis
    Université de Montréal, Kanada

    05/2008 bis 06/2009
    Assistenzarzt
    Innere Medizin A
    Kantonsspital Schaffhausen

    01/2006 bis 01/2008
    Assistenzarzt
    Klinik für Rheumatologie
    Rheumatologie A
    Universitätsspital Zürich

    01/2005 bis 12/2005
    Assistenzarzt
    Rheumatologie
    Reha Rheinfelden

    01/2003 bis 12/2004
    Assistenzarzt
    Innere Medizin B
    FMI Spital Interlaken

    01/2002 bis 12/2002
    Assistenzarzt
    Allgemeine Chirurgie und Orthopädie
    FMI Spital Interlaken


    Mitgliedschaften

    • AerzteGesellschaft des Kantons Zürich AGZ
    • Foederatio medicorum helveticorum FMH
    • Rheumaliga Schweiz, Vorstandsmitglied
    • Schweizerische Ärztegesellschaft für Manuelle Medizin
    • Schweizerische Gesellschaft für Ultraschall in der Medizin SGUM
    • Schweizerischer Verband für Assistenz- und Oberärzte VSAO
    • Schweizerische Gesellschaft für Rheumatologie SGR, Vorstandsmitglied seit 08/2016, Delegationsleiter der Weiterbildungsstättenkommission
    • Zürcher Fachärztegesellschaft für Rheumatologie
  • Publikationen

    Originalarbeiten

    1. Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort.
      Hebeisen M, Neuenschwander R, Scherer A, Exer P, Weber U, Tamborrini G, Micheroli R, Wildi LM, Zufferey P, Nissen MJ, Villiger PM, Bernhard J, Finckh A, van der Horst-Bruinsma IE, Sieper J, Landewé R, van der Heijde D, Ciurea A; rheumatologists of the Swiss Clinical Quality Management Program.
      J Rheumatol. 2018 Apr;45(4):506-512. doi: 10.3899/jrheum.170166.
    2. Nodular Regenerative Hyperplasia of the Liver: A Rare Vascular Complication in Systemic Sclerosis.
      Graf L, Dobrota R, Jordan S, Wildi LM, Distler O, Maurer B.
      J Rheumatol. 2018 Jan;45(1):103-106. doi: 10.3899/jrheum.170292.
    3. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort.
      Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, Kissling RO, Tamborrini G, Wildi LM, Nissen MJ, Zufferey P, Bernhard J, Weber U, Landewé RBM, van der Heijde D, Ciurea A; Rheumatologists of the Swiss Clinical Quality Management Program.
      Ann Rheum Dis. 2017 Sep 22. pii: annrheumdis-2017-211544. doi: 10.1136/annrheumdis-2017-211544.
      PMID: 28939631
    4. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.
      Micheroli R, Hebeisen M, Wildi LM, Exer P, Tamborrini G, Bernhard J, Möller B, Zufferey P, Nissen MJ, Scherer A, Ciurea A; Rheumatologists of the Swiss Clinical Quality Management Program.
      Arthritis Res Ther. 2017 Jul 19;19(1):164. doi: 10.1186/s13075-017-1372-3.
      PMID: 28724442
    5. MRI findings in the knee before and after running, with the focus on long distance running: Documentation of irreversible structural damage? A systematic review.
      Hoessly LM, Wildi LM. Am J Sports Med. 2017 Apr;45(5):1206-1217.
    6. Computer-based diagnostic expert systems in rheumatology: where do we stand in 2014?
      Alder H, Michel BA, Marx C, Tamborrini G, Langenegger T, Bruehlmann P, Steurer J, Wildi LM.
      Int J Rheumatol. 2014;2014:672714
    7. Relevant baseline characteristics for describing patients with knee osteoarthritis: results from a Delphi survey.
      Wildi LM, Hensel A, Wertli M, Michel BA, Steurer J.
      BMC Musculoskelet Disord. 2013 Dec 30;14:369
    8. Assessment of cartilage changes over time in knee osteoarthritis disease-modifying osteoarthritis drug trials using semiquantitative and quantitative methods: pros and cons.
      Wildi LM, Martel-Pelletier J, Abram F, Moser T, Raynauld JP, Pelletier JP.
      Arthritis Care Res (Hoboken). 2013 May;65(5):686-94
    9. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI.
      Wildi LM, Raynauld JP, Martel-Pelletier J, Beaulieu A, Bessette L, Morin F, Abram F, Dorais M, Pelletier JP.
      Ann Rheum Dis. 2011 Jun;70(6):982-9
    10. Relationship between bone marrow lesions, cartilage loss and pain in knee osteoarthritis: results from a randomised controlled clinical trial using MRI.
      Wildi LM, Raynauld JP, Martel-Pelletier J, Abram F, Dorais M, Pelletier JP.
      Ann Rheum Dis. 2010 Dec;69(12):2118-24
    11. Pseudocystic degeneration of the lumbar ligamentum flavum: a little known entity.
      Wildi LM, Kurrer MO, Benini A, Weishaupt D, Michel BA, Brühlmann P..
      J Spinal Disord Tech. 2004 Oct;17(5):395-400
    12. Cross-cultural adaptation of the German version of the spinal stenosis measure.
      Wertli MM, Steurer J, Wildi LM, Held U.
      Eur Spine J. 2014 Jun;23(6):1309-19
    13. Reliability and sensitivity to change of IW-TSE versus DESS magnetic resonance imaging sequences in the assessment of bone marrow lesions in knee osteoarthritis patients: Longitudinal data from the Osteoarthritis Initiative (OAI) cohort.
      Raynauld JP, Wildi LM, Abram F, Moser T, Pelletier JP, Martel-Pelletier J. J. Biomedical Science and Engineering, 2013. 6: p. 337-45
    14. Total Knee Replacement as a Knee Osteoarthritis Outcome: Predictors Derived from a 4-Year Long-Term Observation following a Randomized Clinical Trial Using Chondroitin Sulfate.
      Raynauld JP, Martel-Pelletier J, Dorais M, Haraoui B, Choquette D, Abram F, Beaulieu A, Bessette L, Morin F, Wildi LM, Pelletier JP.
      Cartilage. 2013 Jul;4(3):219-26
    15. Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation.
      Raynauld JP, Martel-Pelletier J, Haraoui B, Choquette D, Dorais M, Wildi LM, Abram F, Pelletier JP.
      Ann Rheum Dis. 2011 Aug;70(8):1382-8

    Narrative Reviews

    1. Osteoarthritis : What internists should know.
      Wildi L
      Internist (Berl). 2015 May;56(5):527-43
    2. Pharmacological therapy of arthrosis.
      Wildi LM
      Z Rheumatol. 2013 Nov;72(9):885-94
    3. Future therapeutics for osteoarthritis.
      Martel-Pelletier J, Wildi LM, Pelletier JP.
      Bone. 2012 Aug;51(2):297-311

    Case Reports

    1. Reversible male infertility under treatment with an anti-TNFα agent: a case report.
      Wildi LM, Haraoui B.
      Ann Rheum Dis. 2012 Mar;71(3):473-4

    Buchkapitel

    1. “Biomarkers in Osteoarthritis” in “Understanding Osteoarthritis from Bench to Bedside”
      Wildi LM, Tamborrini G
      Editors Martel-Pelletier J. and Pelletier J.P. Research Signpost, Kerala, India